Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Safety Analyses From the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study - Talazoparib + Enzalutamide in mCRPC"

223 views
June 20, 2023
Comments 0
Login to view comments. Click here to Login